Open AccessPembrolizumab (Keytruda)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.158
Subject(s) - reimbursement , pembrolizumab , microsatellite instability , medicine , drug , colorectal cancer , family medicine , cancer , political science , pharmacology , health care , allele , biochemistry , chemistry , immunotherapy , law , microsatellite , gene
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses pembrolizumab (Keytruda) 200 mg administered intravenouslyIndication: As monotherapy, for the first-line treatment of adults with metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer